These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35984129)

  • 21. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
    Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
    Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma.
    Yuan Y; Yang B; Qi Z; Han Z; Cai J; Song J
    Front Oncol; 2022; 12():783721. PubMed ID: 35814367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

  • 27. [Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
    Chen Y; Li Q; Zhang J; Gu R; Li K; Zhao G; Yuan H; Feng T; Ou D; Lin P
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2020 Jun; 37(3):469-479. PubMed ID: 32597089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
    Luo C; Liu Z; Ye W; Liu F
    Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
    [No Abstract]   [Full Text] [Related]  

  • 30.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CENPA acts as a prognostic factor that relates to immune infiltrates in gliomas.
    Wang B; Wei W; Long S; Wang L; Yang B; Wu D; Li Z; Li Z; Arshad M; Li X; Chen J
    Front Neurol; 2022; 13():1015221. PubMed ID: 36341103
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Hu Z; Qu S
    Front Immunol; 2021; 12():683572. PubMed ID: 34267752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
    Yang G; Tang S; Zhang J; Qin L
    World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APOL4, a Novel Immune-Related Prognostic Biomarker for Glioma.
    Zhu H; Hu X; Feng S; Li Y; Zhang Y; Qiu S; Chen R; Ye Y; Gu L; Jian Z; Xu X; Xiong X
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Biomarker ZNF311 and Its Correlation With Tumor Progression and Immune Infiltrates in Glioma.
    Ge X; Jiang S; Wang Z; Hu N; Jiang R; Cai Z; Wu B; Zhang Y; Gong P
    World Neurosurg; 2021 Jul; 151():e37-e46. PubMed ID: 33746099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas.
    Zhang X; Liu S; Zhao X; Shi X; Li J; Guo J; Niedermann G; Luo R; Zhang X
    Strahlenther Onkol; 2020 Oct; 196(10):913-921. PubMed ID: 32025804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.